Title: Bronchial Hyperresponsiveness and its Risk Factors in Finnish Adult Population
Description: The aim of the study was to assess the prevalence of bronchial hyperresponsiveness (BHR) in the Finnish adult general population, its determinants and risk factors. Histamine and methacholine challenges were compared to assess their agreement. The association of active and passive smoking with BHR severity was studied in detail. Incident adult asthma in Helsinki over the 11 years follow up was investigated. For the BHR comparison study 79 subjects were included in Kemi, Finland, whereas 292 randomly selected subjects (26-66 years) were included for the Helsinki BHR-study. The follow up study of incident asthma and respiratory symptoms in 2007 included 4302 of those, who had originally (n=6062) taken part in the FinEsS-Helsinki postal survey in 1996. In Kemi, bronchial challenges to methacholine and histamine were performed to each subject in a randomized order. In Helsinki, following the interview, skin prick tests, spirometry, and fractional exhaled nitric oxide (FENO) measurement, the BHR test with histamine was assessed. Provocative doses (PD15FEV1 and PD20FEV1) for histamine and methacholine were assessed. The highest cumulative dose for methacholine was 2.6 mg, and the highest non-cumulative dose for histamine was 1.6 mg. Histamine PD15FEV1 ≤0.4 mg (BHRms) and ≤1.6 mg (BHR) served a cut-off points in the logistic regression analysis. BHR tests with metacholine and histamine tests showed a good agreement in classifying severity of BHR in a population with no previous diagnosis of asthma or chronic bronchitis (weighted kappa 0.64; CI 95% 0.46-0.82). In the general adult population in Helsinki, the prevalance of BHR was 21%, and for BHRms 6% . The main determinants for BHR were a decreased FEV1 and airway obstruction, which yielded over four-fold risk for BHR. Smoking and BHR were dose-dependently associated, and the young age of starting to smoke and exposure to environmental tobacco smoke (ETS), constituted on BHR. Respiratory symptoms, asthma or wheezing in the
Subjects: Bronchial Spasms, Risk Assessment